Targefrin is an innovative agonistic synthetic agent targeting pro-oncogenic EphA2 causing its degradation

Targefrin as anti-metastatic agent in solid tumors:

Targefrin is very effective in suppressing pro-oncogenic EphA2 resulting in marked anti-metastatic properties in tumor models of pancreatic cancer, breast cancer, and prostate cancer; stage seeking funds for IND enabling and phase trials

Targefrin as targeted delivery of chemotherapy to solid tumors:

Targefrin is an effective and innovative platform for targeted delivery of chemotherapy by selectively delivering cytotoxic chemotherapeutic agents to EphA2 rich cancer cells.

Indications: Pancreatic cancer, breast cancer, prostate cancer, colorectal cancer, ovarian cancer, endometrial cancer; stage late pre-clinical